Healthy human T cell
via NAID
Bioengineers at the University of California San Diego have developed a cancer immunotherapy that pairs ultrasound with cancer-killing immune cells to destroy malignant tumors while sparing normal tissue.
The new experimental therapy significantly slowed down the growth of solid cancerous tumors in mice.
The team, led by the labs of UC San Diego bioengineering professor Peter Yingxiao Wang and bioengineering professor emeritus Shu Chien, detailed their work in a paper published Aug. 12 in Nature Biomedical Engineering.
The work addresses a longstanding problem in the field of cancer immunotherapy: how to make chimeric antigen receptor (CAR) T-cell therapy safe and effective at treating solid tumors.
CAR T-cell therapy is a promising new approach to treat cancer. It involves collecting a patient’s T cells and genetically engineering them to express special receptors, called CAR, on their surface that recognize specific antigens on cancer cells. The resulting CAR T cells are then infused back into the patient to find and attack cells that have the cancer antigens on their surface.
This therapy has worked well for the treatment of some blood cancers and lymphoma, but not against solid tumors. That’s because many of the target antigens on these tumors are also expressed on normal tissues and organs. This can cause toxic side effects that can kills cells—these effects are known as on-target, off-tumor toxicity.
“CAR T cells are so potent that they may also attack normal tissues that are expressing the target antigens at low levels,” said first author Yiqian (Shirley) Wu, a project scientist in Wang’s lab.
“The problem with standard CAR T cells is that they are always on—they are always expressing the CAR protein, so you cannot control their activation,” explained Wu.
To combat this issue, the team took standard CAR T cells and re-engineered them so that they only express the CAR protein when ultrasound energy is applied. This allowed the researchers to choose where and when the genes of CAR T cells get switched on.
“We use ultrasound to successfully control CAR T cells directly in vivo for cancer immunotherapy,” said Wang, who is a faculty member of the Institute of Engineering in Medicine and the Center for Nano-ImmunoEngineering, both at UC San Diego. What’s exciting about the use of ultrasound, noted Wang, is that it can penetrate tens of centimeters beneath the skin, so this type of therapy has the potential to non-invasively treat tumors that are buried deep inside the body.
The team’s approach involves injecting the re-engineered CAR T cells into tumors in mice and then placing a small ultrasound transducer on an area of the skin that’s on top of the tumor to activate the CAR T cells. The transducer uses what’s called focused ultrasound beams to focus or concentrate short pulses of ultrasound energy at the tumor. This causes the tumor to heat up moderately—in this case, to a temperature of 43 degrees Celsius (109 degrees Fahrenheit)—without affecting the surrounding tissue. The CAR T cells in this study are equipped with a gene that produces the CAR protein only when exposed to heat. As a result, the CAR T cells only switch on where ultrasound is applied.
The researchers put their CAR T cells to the test against standard CAR T cells. In mice that were treated with the new CAR T cells, only the tumors that were exposed to ultrasound were attacked, while other tissues in the body were left alone. But in mice that were treated with the standard CAR T cells, all tumors and tissue expressing the target antigen were attacked.
“This shows our CAR T-cell therapy is not only effective, but also safer,” said Wu. “It has minimal on-target, off-tumor side effects.”
The work is still in the early stages. The team will be performing more preclinical tests and toxicity studies before it can reach clinical trials.
Original Article: Ultrasound remotely triggers immune cells to attack tumors in mice without toxic side effects
More from: University of California San Diego | Shanghai Jiao Tong University | Prince of Songkla University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Ultrasound cancer immunotherapy
- Immunotherapy may boost survival after lung cancer surgery
Immunotherapy can boost the survival of early-stage lung cancer patients eligible for surgery when it's combined with chemotherapy, a new clinical trial reports.
- This time, it's personal: Enhancing patient response to cancer immunotherapy
Scientists uncover why cancer patients with ARID1A gene mutations are more likely to respond to immunotherapy, discovering ARID1A mutations invite cancer-fighting immune cells into tumors by ...
- How ultrasound and microbubbles could deliver immunotherapy to the brain
Malignant primary brain tumors are the leading cause of cancer deaths among children and young adults with few therapeutic options. Treatments are limited by the blood–brain barrier, a unique ...
- Targeted and immunotherapy drugs for womb cancer
You might have targeted and immunotherapy drugs as part of your treatment for womb cancer. Targeted cancer drugs work by targeting the differences in cancer cells that help them to grow and survive.
- Scientists making progress in less toxic cancer treatment called immunotherapy
BOSTON - Scientists are making progress in using less toxic immunotherapy instead of traditional chemotherapy to fight cancer. Chemotherapy is very effective at treating a variety of cancers ...
Go deeper with Google Headlines on:
Ultrasound cancer immunotherapy
[google_news title=”” keyword=”ultrasound cancer immunotherapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
CAR T-cell therapy
- Galapagos enters deal to boost decentralised CAR-T therapy production
Galapagos has signed a strategic partnership with Blood Centers of America (BCA) to expedite the decentralised production of its chimeric antigen receptor (CAR)-T cell therapies across the US. This ...
- The price of hope: CAR-T therapy in pediatric leukemia
“The advancement of novel therapies like CAR-T in relapsed and refractory pediatric ... 2]. This innovative therapy involves genetically modifying a patient’s native T-cells – immune cells with the ...
- Bristol Myers' Breyanzi bags FDA nod to follow CAR-T rivals Gilead, Novartis into follicular lymphoma
The FDA has broadened the use of Bristol Myers Squibb’s CAR-T therapy Breyanzi to another type of blood cancer. | The FDA has broadened the use of Bristol Myers Squibb’s CAR-T therapy Breyanzi to ...
- Best Life: CAR T-cell therapy
CAR T-cell therapy is a type of cellular immunotherapy used for patients with certain types of leukemias and lymphomas, as well as multiple myeloma. It uses the patient’s immune system cells to attack ...
- Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for B ...
Go deeper with Google Headlines on:
CAR T-cell therapy
[google_news title=”” keyword=”CAR T-cell therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]